These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 37246403)
1. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis. Liu Y; An C; Liu P; Yang F; Zhao Q Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403 [TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674 [TBL] [Abstract][Full Text] [Related]
3. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905 [TBL] [Abstract][Full Text] [Related]
4. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742 [TBL] [Abstract][Full Text] [Related]
5. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Cao H; Rao X; Jia J; Yan T; Li D Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605 [TBL] [Abstract][Full Text] [Related]
6. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. ; Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458 [TBL] [Abstract][Full Text] [Related]
7. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis. Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. Liu XY; Zhang N; Chen R; Zhao JG; Yu P J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis. Woodhams LM; Chalmers L; Sim TF; Yeap BB; Schlaich MP; Schultz C; Hillis GS J Diabetes Complications; 2023 Jun; 37(6):108456. PubMed ID: 37127001 [TBL] [Abstract][Full Text] [Related]
10. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Rigato M; Fadini GP; Avogaro A Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697 [TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes. Griffin TP; Dinneen SF Ann Intern Med; 2020 Oct; 173(8):JC40. PubMed ID: 33075260 [TBL] [Abstract][Full Text] [Related]
12. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex. Kitaoka K; Yano Y; Nagasu H; Kanegae H; Chishima N; Akiyama H; Tamura K; Kashihara N BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38816204 [TBL] [Abstract][Full Text] [Related]
13. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis. Yu B; Dong C; Hu Z; Liu B Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074 [TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Colacci M; Fralick J; Odutayo A; Fralick M Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926 [TBL] [Abstract][Full Text] [Related]
15. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585 [TBL] [Abstract][Full Text] [Related]
16. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Feng C; Wu M; Chen Z; Yu X; Nie Z; Zhao Y; Bao B Int Urol Nephrol; 2019 Apr; 51(4):655-669. PubMed ID: 30830656 [TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838 [TBL] [Abstract][Full Text] [Related]
18. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. Lin Y; Mok M; Harrison J; Battistella M; Farrell A; Leung M; Cheung C Transplant Rev (Orlando); 2023 Jan; 37(1):100729. PubMed ID: 36427372 [TBL] [Abstract][Full Text] [Related]
19. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Seidu S; Kunutsor SK; Topsever P; Khunti K Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161 [TBL] [Abstract][Full Text] [Related]
20. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Bantounou MA; Sardellis P; Thuemmler R; Black Boada D; Kaczmarek J; Mahmood R; Plascevic J; Philip S Diabetes Obes Metab; 2024 Feb; 26(2):710-720. PubMed ID: 38031239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]